Pfizer has announced around €300 million capital investment in its Irish operations which will support the further development of existing manufacturing sites in Grange Castle, Newbridge and Ringaskiddy.

The investment will provide additional manufacturing and laboratory capacity creating approximately 300 roles, with additional anticipated construction roles in Ringaskiddy, Cork. The investment and additional roles will be completed over the next two to three years.

The investment and roles being created will upgrade and enhance existing facilities, expand manufacturing and laboratory capacity and add new technologies to ensure Pfizer is ready to support the next wave of medical innovations. Part of the investment includes the initial stage of a project to construct a development facility on the existing Ringaskiddy site to manufacture pharmaceutical compounds for Pfizer’s clinical trials globally. This is a very important development as it expands Pfizer’s role in Ireland from the manufacture of already approved medicines into supporting the earlier phases of new medicine development.

-- Advertisement --

The Irish sites manufacture leading medicines and vaccines in the areas of arthritis, inflammation, cancer, anti-infectives, haemophilia, pain and stroke. The roles being recruited for comprise a broad range of highly skilled roles including; analysts, technicians, engineers, scientists, technologists, quality specialists, data analysts and chemists.

Dr Paul Duffy, Vice President, Pfizer Global Supply said: "Pharmaceutical manufacturing in Ireland continues to perform very well contributing strongly to exports and economic growth and provides excellent career opportunities. Pfizer has an extensive global and U.S. footprint with operations in over 125 countries worldwide and we are very pleased with today’s announcements which will strengthen our Irish operations and bring our total headcount in Ireland to 4,000. It is also particularly exciting that our Ringaskiddy site has been chosen as the location to manufacture investigational compounds for our clinical trials globally and we look forward to seeing that new facility become operational."